Literature DB >> 29496081

The endovascular management of neurofibromatosis-associated aneurysms: A systematic review.

David Bargiela1, Misha M Verkerk2, Ian Wee3, Kiera Welman4, Eugene Ng5, Andrew M T L Choong6.   

Abstract

BACKGROUND: Neurofibroblastoma (NF) or Von Recklinghausen disease, is an autosomal dominant disorder affecting one in 3000 individuals. Cardinal features of NF include multiple café-au-lait macules, benign neurofibromas, and iris hamartomas. Albeit less common, vascular lesions of medium and large-sized arteries and veins are a well-recognized complication, which can lead to fatal consequences such as rupture.
METHOD: A systematic review was conducted as per the Preferred Reporting Instructions for Systematic Reviews and Meta-analysis (PRISMA) guidelines utilizing PubMed, EMBASE, and Cochrane databases.
RESULTS: There were 59 articles identified involving 66 patients (mean age 44.3 ± 30 years), of which 89% had neurofibromatosis type 1. There were 63.6% of patients who presented with aneurysm rupture, 33.3% presented with intact symptomatic aneurysms, and 3.1% presented with intact asymptomatic aneurysms. Anatomically, 4.5% of patients suffered from intracranial aneurysms; 12.1% suffered from visceral artery aneurysms (including hepatic, superior mesenteric, gastroduodenal and renal arteries), and other patients suffered from aneurysms within the chest, abdomen, pelvis, upper limbs and neck. Amongst the various endovascular procedures, coiling was performed in 83.3% of cases. There were 12 covered stents employed in 10 patients (18.2%), of which 7 were balloon-expandable grafts; 2 were self-expandable graft; 3 were not mentioned. The rates of major and minor complications were 15% and 6% respectively, with 4 cases (6%) of perioperative death. On a mean follow-up of 15 months (range 1.5-72 months), two patients developed a distant vascular lesion from the treated lesion.
CONCLUSION: Endovascular management is safe and effective even in hemodynamically unstable neurofibroblastoma patients at all ages. Vascular tree screening should be conducted in clinically suspicious patients to prevent fatal aneurysmal complications. A formal meta-analysis could not be performed due to the lack of randomized controlled trials.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aneurysm; Endovascular surgery; Neurofibroblastoma; Vasculopathy; Von Recklinghausen

Mesh:

Year:  2017        PMID: 29496081     DOI: 10.1016/j.ejrad.2017.12.014

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  5 in total

1.  Spontaneous rupture of the pancreatic arcade artery caused by neurofibromatosis type 1 successfully treated using emergency transcatheter arterial embolization, partial intra-aortic balloon occlusion, and stent graft placement: a case report and review of the literature.

Authors:  Ryo Morita; Daisuke Abo; Takeshi Soyama; Yuki Yoshino; Toru Yoshikawa; Tasuku Kimura; Kohsuke Kudo
Journal:  CVIR Endovasc       Date:  2020-07-26

2.  Successful Surgical Reconstruction of a Ruptured Brachial Artery Aneurysm in a Patient With Type 1 Neurofibromatosis.

Authors:  Kyra J Degenaar; Britt Barvelink; Syert Nienhuis; Bernard H Elsman
Journal:  EJVES Short Rep       Date:  2019-05-11

3.  Treatment of ruptured rectal artery aneurysm in a patient with neurofibromatosis.

Authors:  Hidehiko Nemoto; Kensaku Mori; Yohei Takei; Shunsuke Kikuchi; Sodai Hoshiai; Yoshiyuki Yamamoto; Takahito Nakajima
Journal:  CVIR Endovasc       Date:  2022-08-04

Review 4.  Life-threatening brachial artery hemorrhage and a lethal outcome in patients with neurofibromatosis type 1: two case reports and a review of the literature.

Authors:  Jisun Lee; Yook Kim
Journal:  J Int Med Res       Date:  2021-06       Impact factor: 1.671

5.  Co-occurrence of neurofibromatosis type 1 and optic nerve gliomas with autosomal dominant polycystic kidney disease type 2.

Authors:  Ramón Peces; Rocío Mena; Yolanda Martín; Concepción Hernández; Carlos Peces; Dolores Tellería; Emilio Cuesta; Rafael Selgas; Pablo Lapunzina; Julián Nevado
Journal:  Mol Genet Genomic Med       Date:  2020-06-13       Impact factor: 2.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.